Back to top

pharmaceuticals: Archive

Zacks Equity Research

RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome

Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.

BAYRYNegative Net Change AGENNegative Net Change RARENegative Net Change IMCRPositive Net Change

Ekta Bagri

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.

BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change

Kinjel Shah

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.

VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change

Ahan Chakraborty

NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.

NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change

Zacks Equity Research

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.

PFEPositive Net Change BMRNNegative Net Change EXELPositive Net Change PBYIPositive Net Change

Kinjel Shah

Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change

Kinjel Shah

AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock

ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.

NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Ekta Bagri

Will Strong Asceniv Sales Drive ADMA Biologics Further?

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change

Ekta Bagri

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

BEAMPositive Net Change NTLANegative Net Change KRYSNegative Net Change MGTXNegative Net Change

Kanishka Das

Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

AZNPositive Net Change RHHBYNegative Net Change BMYNegative Net Change MRKPositive Net Change

Ahan Chakraborty

Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.

NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change

Kinjel Shah

J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?

JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.

BSXPositive Net Change JNJPositive Net Change MDTPositive Net Change SYKPositive Net Change

Zacks Equity Research

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.

SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change

Zacks Equity Research

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

ASR, INSW, and BCRX lead a high-efficiency stock screen with strong earnings surprises and solid fundamentals amid market volatility.

BCRXNegative Net Change ASRPositive Net Change RRGBPositive Net Change ASCNegative Net Change INSWNegative Net Change

Zacks Equity Research

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.

BAYRYNegative Net Change AGENNegative Net Change KRYSNegative Net Change IMCRPositive Net Change

Zacks Equity Research

Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU

AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.

BAYRYNegative Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPPositive Net Change

Ekta Bagri

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change

Zacks Equity Research

Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

SNYPositive Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change

Kinjel Shah

Merck Moves Past 50-Day Average: How to Play MRK Stock Now

MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.

MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change

Ekta Bagri

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.

ADMAPositive Net Change TAKPositive Net Change

Mark Vickery

Top Analyst Reports for JPMorgan, Novartis & AT&T

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.

JPMPositive Net Change NEENegative Net Change NVSPositive Net Change TPositive Net Change JCIPositive Net Change APHPositive Net Change UTMDNegative Net Change PPIHNegative Net Change

David Bartosiak

Can Hims Recover after Novo Nordisk Diss?

Hims shares tumbled after Novo Nordisk canceled its partnership. Can the stock recover?

HIMSPositive Net Change

Zacks Equity Research

MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.

JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change EXELPositive Net Change

Zacks Equity Research

CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

NVOPositive Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRPositive Net Change